Oryzon Secures EMA Approval to Advance iadademstat in Essential Thrombocythemia
Event summary
- Oryzon Genomics received European Medicines Agency (EMA) approval to initiate a Phase II study (IDEAL) of iadademstat for essential thrombocythemia (ET).
- The study will enroll adult ET patients resistant or intolerant to hydroxyurea, conducted across multiple sites in Spain.
- Iadademstat, an LSD1 inhibitor, will be administered for up to 24 weeks, with a potential 24-week extension.
- Preliminary data from trials combining iadademstat with azacitidine and venetoclax showed a 100% overall response rate (ORR) and 90% strict complete remission (CR) rate in acute myeloid leukemia (AML).
The big picture
Oryzon's strategy to expand iadademstat's use beyond oncology into hematology addresses a significant clinical need, as a substantial portion of ET patients develop resistance or intolerance to existing treatments. The company's focus on LSD1 inhibition, validated by positive results with other inhibitors, positions iadademstat as a potentially differentiated therapeutic option. However, the success of the IDEAL trial is crucial to realizing this potential and justifying the investment in a broader epigenetic pipeline.
What we're watching
- Clinical Efficacy
- The IDEAL trial's results will be critical in determining if iadademstat's LSD1 inhibition mechanism translates to meaningful clinical benefit in ET patients, particularly given the unmet need for alternatives to hydroxyurea.
- Regulatory Pathway
- Success in the Phase II trial will dictate the speed and likelihood of a potential market authorization application, which could significantly impact Oryzon’s valuation.
- Pipeline Expansion
- How Oryzon balances the advancement of iadademstat across multiple oncology and hematology indications will influence resource allocation and overall development timelines.
Related topics